Monoclonal antibodies against prostate specific membrane...

C - Chemistry – Metallurgy – 07 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C07K 16/30 (2006.01) A61P 35/00 (2006.01)

Patent

CA 2598454

The invention pertains to anti-PSMA antibodies that lack fucosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity as compared to the fucosylated form of the antibodies. The invention also provides host cells that express the anti-PSMA antibodies that lack fucosyl residues, wherein the host cells are deficient for a fucosyl transferase. Methods of using the antibodies to inhibit the growth of PSMA+ cells, such as tumor cells, are also provided.

La présente invention concerne des anticorps anti-PSMA qui sont dépourvus de résidus fucosyle. Les anticorps selon l'invention présentent une plus forte activité de cytotoxicité cellulaire dépendant des anticorps que la forme fucosylée des anticorps. Cette invention concerne également des cellules hôtes qui expriment les anticorps anti-PSMA dépourvus de résidus fucosyle, lesdites cellules hôtes étant déficientes en fucosyl transférase; et des méthodes d'utilisation desdits anticorps pour inhiber la croissance des cellules PSMA+, telles que les cellules tumorales.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Monoclonal antibodies against prostate specific membrane... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Monoclonal antibodies against prostate specific membrane..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibodies against prostate specific membrane... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1493434

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.